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Genetic	  factors	  of	  obesity	  and	  eating	  disorders:	  Copy	  number	  variations	  (CNV)	  involving	  SH2B1	  
Introduction:	  Obesity	  is	  a	  growing	  public	  health	  issue.	  (1,2)	  It’s	  prevalence	  as	  well	  as	  the	  prevalence	  of	  the	  comorbidities	  have	  increased.(3)	  The	  obesity	  epidemic	  is	  clearly	  associated	  with	  the	  recent	  availability	  of	  highly	  palatable	  and	  inexpensive	  caloric	  food.	  In	  this	  new	  “obesogenic”	  environment	  however,	  some	  individuals	  remain	  lean	  and	  others	  develop	  morbid	  obesity.	  Among	  the	  many	  factors	  underlying	  this	  variance	  of	  adiposity,	  genetics	  play	  a	  key	  role.	  Twin	  studies	  have	  estimated	  the	  BMI	  heritability	  (h2)	  between	  40	  and	  70%.	  GWAS	  (Genome-­‐Wide	  Association	  Studies)	  have	  identified	  common	  variants	  that	  point	  towards	  new	  pathways,	  but	  their	  effect	  size	  are	  too	  weak	  to	  be	  of	  any	  use	  in	  the	  clinic.	  Studies	  have	  also	  focused	  on	  genes	  and	  genomic	  regions	  that	  are	  associated	  with	  very	  high	  risks	  of	  obesity.	  (4)	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b)	  CNVs	  involving	  SH2B1	  At	  the	  same	  16p11.2	  locus,	  a	  second	  non-­‐overlapping	  recurrent	  CNV	  encompassing	  SH2B1,	  upstream	  of	  the	  aforementioned	  rearrangement	  has	  been	  published.(4)	  (8)	  SNPs	  in	  this	  gene	  have	  been	  associated	  with	  BMI	  in	  GWAS	  studies	  and	  KO	  mice	  models	  confirmed	  this	  association.	  	  	  Bokuchova	  et	  al	  have	  reported	  an	  association	  between	  deletions	  encompassing	  this	  gene	  and	  severe	  early	  onset	  obesity,	  as	  well	  as	  insulin	  resistance.	  SH2B1	  is	  known	  to	  be	  an	  important	  factor	  in	  insulin	  and	  leptin	  signaling.	  In	  their	  study,	  they	  identified	  three	  patients	  who	  carried	  this	  220-­‐kb	  16p11.2	  deletion	  (28.73-­‐28.95	  Mb)	  and	  presented	  severe	  early-­‐onset	  obesity.	  This	  suggested	  an	  association	  between	  this	  SH2B1-­‐containing	  220-­‐kb	  (28.73-­‐28.95	  Mb)	  deletion	  and	  a	  severe	  form	  of	  obesity.(8)	  These	  patients	  rapidly	  gained	  weight	  in	  their	  first	  years	  of	  life	  and	  the	  excess	  weight	  was	  predominantly	  fat	  mass.	  Severe	  insulin	  resistance	  was	  recorded.(8)	  Far	  less	  is	  known,	  however,	  on	  the	  full	  spectrum	  of	  clinical	  symptoms	  associated	  with	  this	  CNV.(4)	  	  This	  project	  consisted	  in	  collecting	  and	  analyzing	  data	  to	  fully	  characterize	  the	  phenotype	  associated	  with	  this	  rearrangement.	  We	  here	  report	  a	  large	  series	  of	  patients	  (102)	  with	  imbalances	  that	  include	  the	  SH2B1	  gene	  region	  in	  16p11.2.	  Patients	  were	  mainly	  ascertained	  from	  cohorts	  of	  DD/ID	  patients.	  We	  collected	  mainly	  anthropometric,	  cytomolecular	  and	  medical	  data.	  We	  found	  that	  deletions	  and	  duplications	  in	  this	  region	  are	  significantly	  enriched	  in	  patients	  ascertained	  for	  DD/ID	  when	  compared	  to	  the	  general	  population.	  	  The	  effect	  on	  BMI	  is	  clearly	  demonstrated	  in	  deletion	  carriers,	  and	  a	  mirror	  effect	  with	  decreased	  BMI	  is	  visible	  in	  males	  only.	  An	  effect	  on	  HC	  is	  also	  visible	  after	  gender	  stratification.	  
	  
Patients	  and	  Methods	  
a)	  Patients	  This	  study	  was	  reviewed	  and	  approved	  by	  the	  institutional	  review	  board	  of	  the	  FBM-­‐UNIL.	  Carriers	  were	  ascertained	  through	  several	  cohorts	  (Table	  1).	  	  EU	  Consortium:	  data	  was	  collected	  retrospectively	  and	  anonymously	  on	  questionnaires	  filled	  by	  physicians	  who	  prescribed	  the	  comparative	  genomic	  hybridization	  (CGH).	  These	  analyses	  were	  performed	  for	  patient	  care	  purpose	  only.	  Consequently,	  research	  based	  informed	  consent	  was	  not	  required	  by	  the	  institutional	  review	  board	  of	  the	  University	  of	  Lausanne	  which	  granted	  an	  exemption	  for	  this	  part	  of	  the	  data	  collection.	  Details	  on	  ascertainment	  and	  data	  collection	  for	  other	  cohorts	  have	  been	  previously	  published(7,9)	  and	  are	  presented	  in	  Supplemental	  Information.	  
b)	  Anthropometric	  measures	  The	  accepted	  standard	  measure	  of	  overweight	  and	  obesity	  for	  children	  two	  years	  of	  age	  and	  older	  is	  the	  body	  mass	  index	  (BMI).(10)	  Adults	  with	  a	  BMI	  between	  25	  and	  30	  are	  considered	  overweight;	  those	  with	  a	  BMI	  ≥30	  are	  considered	  to	  be	  obese.	  Unlike	  adults,	  children	  grow	  in	  height	  as	  well	  as	  weight.	  Thus,	  the	  norms	  for	  BMI	  in	  children	  vary	  with	  age	  and	  sex.	  Obesity	  in	  children	  is	  defined	  throughout	  the	  study	  by	  a	  BMI>+2SD	  (Standard	  Deviation).	  Z-­‐scores	  were	  computed	  according	  to	  norms	  matching	  the	  geographic	  origin	  of	  the	  carrier	  (eg.	  for	  children	  between	  the	  ages	  of	  2	  and	  20	  years	  from	  the	  USA,	  BMI	  reference	  standards	  have	  been	  published	  in	  2000	  by	  the	  Centers	  for	  Disease	  Control	  (Figure	  2A-­‐B	  )).	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c)	  Statistical	  analyses	  Two-­‐tailed	  Fisher’s	  exact	  test	  was	  used	  to	  compare	  frequencies	  of	  the	  deletion	  and	  the	  duplication	  in	  patients	  and	  controls.	  Two-­‐tailed	  Student’s	  t	  test	  was	  performed	  to	  assess	  whether	  BMI,	  height,	  weight	  and	  HC	  Z	  scores	  of	  deletion	  and	  duplication	  carriers	  were	  different	  from	  zero	  (general	  population	  mean).	  Wilcoxon	  Rank	  sum	  test	  were	  also	  systematically	  performed	  to	  avoid	  issues	  related	  to	  non	  normal	  distribution.	  These	  tests	  were	  computed	  by	  using	  standard	  packages	  written	  in	  «	  R	  ».	  
Results	  102	  carriers	  of	  a	  rearrangement	  overlapping	  the	  ∼200	  kb	  16p11.2	  BP2-­‐BP3	  region	  are	  included	  in	  our	  study.	  The	  boundaries	  of	  these	  rearrangements	  include:	  BP1-­‐BP3,	  BP1-­‐BP4,	  BP2-­‐BP3,	  BP2-­‐BP4	  and	  exclude	  BP5	  (Figure	  1)	  Ascertainment	  of	  deletion	  and	  duplication	  carriers	  is	  reported	  in	  Table	  1.	  The	  deletion	  was	  identified	  in	  42	  out	  of	  30'635	  patients	  with	  DD/ID	  (Developmental	  Delay/Intellectual	  Disability),	  showing	  a	  frequency	  of	  ∼0.1%.	  This	  is	  significantly	  higher	  (12	  fold	  increase)	  than	  the	  frequency	  observed	  in	  the	  general	  population	  (0.01%),	  (OR	  =12;	  p-­‐value	  =	  1e-­‐10)	  confirming	  the	  association	  between	  this	  deletion	  and	  DD/ID.	  Two	  additional	  carriers	  were	  identified	  in	  ASD	  (Autism	  Spectrum	  Disorder)	  and	  ADHD	  (Attention	  Deficit	  Hyperactivity	  Disorder)	  cohorts	  (n=510	  and	  591	  respectively),	  which	  show	  similar	  frequencies	  ∼0.2%.	  	  The	  duplication	  was	  less	  frequent	  in	  the	  DD/ID	  cohort	  (26/30635;	  0.08%)	  and	  more	  common	  in	  the	  general	  population	  resulting	  in	  a	  lower	  but	  significant	  enrichment	  in	  the	  DD/ID	  group	  (OR=2.6	  and	  a	  p=5e-­‐03)	  	  (Table	  1).	  	  No	  duplication	  cases	  were	  found	  in	  the	  smaller	  ASD	  or	  ADHD	  cohorts.	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b)	  Anthropometric	  Results	  :	  Head	  Circumference	  (HC)	  Macro	  and	  microcephaly	  are	  two	  important	  phenotypes	  associated	  with	  the	  proximal	  16p11.2	  BP4-­‐BP5	  rearrangement.	  We	  therefore	  investigated	  the	  effect	  of	  SH2B1	  rearrangement	  on	  Head	  Circumference	  (HC)	  and	  overall,	  the	  deletion	  or	  the	  duplication	  does	  not	  significantly	  impact	  HC.	  The	  mean	  Z-­‐score	  is	  =0.28	  (p=0.37)	  and	  =-­‐0.54	  (p=0.11)	  for	  the	  deletion	  and	  duplication	  carriers	  respectively	  when	  compared	  to	  the	  norm.	  The	  effect	  on	  HC	  becomes	  visible	  after	  stratifying	  by	  gender	  (Figure	  6).	  Males	  carrying	  the	  duplication	  show	  decreased	  HC,	  mean	  HC	  Z-­‐score	  =-­‐1.88	  (p=3.6e-­‐02).	  No	  effect	  is	  present	  in	  females	  carrying	  the	  duplication	  (mean	  HC	  Z-­‐score	  =	  -­‐0.07;	  p=0.79).	  Gender	  stratification	  in	  the	  deletion	  carriers	  reveals	  no	  differential	  effect	  on	  HC	  (mean	  HC	  Z-­‐score	  =	  0.065	  (p=0.9)	  and	  0.37	  (p=0.29)	  in	  females	  and	  males	  respectively.	  
c)	  Anthropometric	  Results	  :	  BMI	  SH2B1	  VS.	  “Classic”	  29.5-­30.1	  	  The	  effect	  of	  the	  non-­‐overlapping	  29.5-­‐30.1	  deletion	  and	  duplication	  have	  been	  previously	  published	  and	  are	  similar	  to	  those	  observed	  in	  the	  SH2B1	  region.(7)	  We	  therefore	  compared	  the	  magnitude	  of	  these	  effects	  between	  the	  2	  regions	  (Figure	  8).	  The	  effect	  of	  the	  SH2B1	  region	  on	  BMI	  is	  slightly	  smaller	  overall,	  but	  not	  significantly	  different	  when	  compared	  to	  the	  29.5-­‐30.1	  region:	  ΔZ-­‐score	  =	  -­‐0.32	  for	  the	  deletion	  and	  +0.25	  for	  the	  duplication.	  The	  same	  comparison	  was	  performed	  after	  gender	  stratification	  (Figure	  9).	  The	  SH2B1	  deletion	  has	  a	  weaker	  effect	  across	  genders,	  but	  no	  significant	  difference	  between	  the	  2	  regions	  is	  observed:	  ΔZ-­‐score	  =	  -­‐0.54	  for	  females	  and	  -­‐0.2	  for	  males.	  For	  the	  duplication,	  low	  BMI	  is	  observed	  in	  all	  subgroups	  except	  for	  females	  carrying	  the	  SH2B1	  duplication	  resulting	  in	  a	  significant	  difference	  between	  SH2B1	  and	  29.5-­‐30.1	  females:	  ΔZ-­‐score	  =	  +1.04	  (p=0.04).	  	  
d)	  Medical	  history:	  Medical	  history	  was	  only	  available	  for	  carriers	  ascertained	  on	  the	  basis	  of	  neurodevelopmental	  disorders.	  Among	  neurological	  symptoms,	  hypotonia	  is	  the	  most	  frequently	  reported	  symptom	  in	  20%	  and	  6.5%	  of	  deletion	  and	  duplication	  carriers	  respectively.	  Seizures	  were	  reported	  in	  7%	  and	  13%	  of	  deletion	  and	  duplication	  carriers	  respectively	  (Table	  2).	  Behavioral	  and	  psychiatric	  issues	  are	  prevalent	  with	  ASD	  as	  well	  as	  ADHD	  being	  diagnosed	  in	  approximately	  1/5th	  of	  deletion	  carriers.	  Cumulatively,	  behavioral	  issues	  are	  reported	  in	  half	  of	  both	  deletion	  and	  duplication	  carriers.	  	  Malformations	  were	  infrequent	  and	  only	  a	  few	  orthopedic,	  cardiac	  and	  digestive	  were	  reported	  in	  more	  than	  2	  carriers.	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Discussion	  Genomic	  disorders	  encompassing	  SH2B1	  are	  less	  frequent	  (by	  approximately	  4-­‐5	  times)	  than	  the	  neighboring	  600kb	  16p11.2	  rearrangements.	  	  Very	  few	  data	  is	  therefore	  available	  for	  these	  rearrangements.	  We	  show	  in	  this	  large	  series	  that	  both	  the	  deletion	  and	  the	  duplication	  are	  significantly	  enriched	  in	  groups	  of	  patients	  ascertained	  for	  DD/ID.	  When	  compared	  to	  the	  600kb	  BP4-­‐5	  rearrangements,	  the	  neurodevelopmental	  impact	  of	  the	  “SH2B1	  deletion”	  is	  similar	  or	  higher,	  but	  the	  effect	  of	  the	  “SH2B1	  duplication”	  is	  lower	  (Table	  1).	  	  	  We	  confirm	  the	  increase	  of	  BMI	  (+1.26	  SD)	  associated	  the	  SH2B1	  deletion,	  obesity	  being	  present	  in	  40.9%	  of	  carriers.	  	  Strikingly,	  the	  reciprocal	  duplication	  shows	  a	  mirror	  effect	  on	  BMI	  only	  after	  gender	  stratification.	  Male	  carriers	  but	  not	  females	  present	  a	  decrease	  in	  BMI	  (-­‐1.55	  SD).	  This	  represents	  to	  our	  knowledge	  the	  second	  case	  of	  a	  correlation	  between	  gene	  dosage	  and	  BMI.	  It	  is	  unclear	  why	  the	  mirror	  effect	  on	  BMI	  is	  not	  observed	  in	  female	  but	  intriguingly,	  a	  similar	  gender	  effect	  was	  observed	  in	  males	  carrying	  the	  BP4-­‐5	  600kb	  who	  presented	  lower	  BMIs	  and	  higher	  risk	  of	  being	  underweight	  when	  compared	  to	  females.	  	  When	  looking	  at	  HC	  results,	  we	  could	  not	  find	  anything	  confirming	  the	  previously	  published	  association	  between	  deletion	  and	  increased	  HC	  and	  its	  reciprocal	  mirror	  effect	  with	  the	  duplication.(7)	  The	  only	  thing	  concomitant	  with	  this	  association	  appeared	  after	  gender	  stratification,	  with	  the	  males	  carrying	  the	  duplication	  showing	  reduced	  HC	  (-­‐1.88	  SD).	  The	  SH2B1	  genomic	  disorder	  is	  similar	  in	  many	  aspects	  to	  the	  BP4-­‐5	  rearrangements.	  This	  is	  true	  for	  BMI,	  for	  HC	  as	  well	  as	  the	  neuropsychiatric	  symptoms.	  For	  SH2B1	  deletion	  carriers,	  the	  frequency	  of	  seizures/epilepsy	  (7%)	  is	  lower	  to	  those	  reported	  in	  carriers	  of	  the	  BP4-­‐5	  deletion	  carriers	  (24%)	  but	  ASD	  frequency	  is	  similar	  (18%	  and	  15%	  respectively).	  Detailed	  phenotyping	  is	  required	  to	  evaluate	  the	  finer	  similarities	  between	  the	  2	  genomic	  disorders.	  	  The	  deletion	  as	  well	  as	  the	  duplication	  do	  not	  appear	  to	  be	  “malformation	  syndromes”.	  We	  did	  not	  observe	  recurrent	  anomalies	  and	  did	  not	  confirm	  the	  association	  with	  kidney	  and	  urinary	  tracts	  malformations	  previously	  reported.(11)	  Several	  hypothesis	  may	  be	  formulated	  to	  explain	  the	  striking	  phenotypic	  concordance	  between	  these	  2	  non-­‐overlapping	  regions:	  	  i)	  A	  gene	  or	  a	  series	  of	  genes	  involved	  in	  the	  same	  neurodevelopmental	  and	  energy	  balance	  mechanism	  are	  present	  in	  2	  independent	  contiguous	  regions	  at	  the	  16p11.2	  locus.	  	  ii)	  These	  2	  regions	  are	  dependent	  and	  one	  region	  may	  control	  the	  expression	  of	  genes	  in	  the	  other	  region.	  	  Considering	  these	  2	  hypotheses,	  we	  investigated	  the	  possibility	  of	  a	  cumulative	  effect	  on	  the	  aforementioned	  traits,	  in	  carriers	  of	  CNVs	  overlapping	  both	  regions.	  	  We	  identified	  3	  deletions	  and	  5	  duplications	  carriers.	  BMI	  effects	  of	  both	  rearrangements	  are	  confirmed,	  with	  deletions	  cases	  having	  all	  increased	  BMI	  (mean	  =	  3.9	  SD,	  average	  =	  3.44	  SD),	  and	  duplication	  cases	  having	  the	  opposite	  mirror	  effect	  (mean	  =	  -­‐2.74	  SD,	  average	  =	  -­‐2.8	  SD).	  These	  effects	  seem	  stronger	  than	  what	  is	  observed	  in	  CNVs	  covering	  each	  region	  separately,	  but	  larger	  sample	  size	  is	  required.	  	  Regarding	  HC,	  we	  observed	  a	  trend	  towards	  lower	  Z-­‐score	  in	  duplication	  carriers,	  as	  described	  in	  previous	  papers	  (7)	  (mean	  =	  -­‐1.07	  SD,	  average	  =	  -­‐1.15	  SD).	  No	  data	  was	  available	  for	  deletion	  carriers	  concerning	  Head	  Circumference.	  	  While	  the	  BP4-­‐5	  and	  the	  SH2B1	  genomic	  disorders	  may	  be	  similar	  at	  the	  phenotypic	  level,	  they	  differ	  at	  the	  genetic	  level.	  There	  is	  a	  3-­‐fold	  difference	  in	  size	  and	  number	  of	  genes	  (8:30).	  In	  the	  BP4-­‐5	  region,	  4	  genes	  have	  already	  been	  linked	  to	  phenotypes	  (KTCD13/ALDOA/MAPK3	  for	  head	  circumference	  and	  PRRT2	  for	  epilepsy)	  (12,13).	  Regarding	  the	  effect	  on	  BMI,	  SH2B1	  has	  been	  the	  sole	  candidate	  gene	  for	  the	  distal	  200kb	  region	  (14).	  Intriguingly,	  point	  mutations	  of	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SH2B1	  have	  recently	  been	  reported	  in	  5	  patients	  with	  obesity	  as	  well	  as	  neurocognitive	  and	  language	  disorder	  suggesting	  that	  SH2B1	  may	  also	  have	  an	  effect	  on	  neurodevelopment.	  	  The	  same	  study	  reported(14)impaired	  NGF-­‐induced	  neuronal	  differentiation	  in	  vitro	  related	  to	  SH2B1	  loss	  of	  function.	  This	  observation	  also	  suggests	  that	  many	  deleterious	  mutations	  impacting	  central	  regulation	  of	  energy	  balance	  may	  also	  impact	  neurodevelopment	  on	  a	  broader	  scale,	  leading	  to	  the	  frequently	  reported	  association	  between	  developmental	  delay	  and	  obesity.	  (15,16)	  	  
Conclusions	  :	  This	  study	  confirms	  significant	  increase	  of	  BMI	  in	  SH2B1	  deletions	  carriers,	  which	  was	  suggested	  by	  previous	  studies.	  This	  highlights	  again	  the	  importance	  of	  rare	  variants	  in	  common	  disorders.	  Intriguingly,	  a	  mirror	  effect	  of	  the	  duplication	  on	  BMI	  is	  visible	  in	  males	  only.	  This	  is	  also	  true	  for	  the	  decrease	  in	  HC	  in	  males	  carrying	  the	  duplications.	  	  In	  addition	  to	  energy	  balance	  and	  anthropometric	  effects,	  cognitive	  and	  behavioral	  phenotypes	  are	  also	  reminiscent	  of	  the	  BP4-­‐5	  600kb	  deletion.	  This	  raises	  the	  question	  of	  a	  possible	  relationship	  between	  the	  2	  loci.	  
Personal	  thoughts	  on	  this	  Master	  Project	  From	  a	  personal	  point	  of	  view,	  this	  project	  has	  brought	  me	  a	  lot.	  When	  I	  chose	  this	  subject,	  I	  had	  almost	  no	  idea	  on	  what	  it	  meant	  and	  moreover	  on	  research	  itself.	  Having	  done	  this	  work	  helped	  me	  understand	  better	  the	  significance	  and	  importance	  of	  medical	  genetics	  in	  the	  modern	  practice	  of	  medicine.	  It	  also	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  to	  open	  my	  mind	  to	  the	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  side	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  future	  job,	  as	  well	  as	  giving	  me	  tools	  and	  ideas	  for	  further	  research	  projects.	  I	  sincerely	  hope	  that	  this	  work	  will	  lead	  to	  new	  research	  projects	  and	  ideas,	  to	  help	  understand	  the	  complexity	  of	  this	  topic	  and	  improve	  medical	  practice,	  as	  well	  as	  medical	  care	  for	  patients	  concerned	  with	  these	  issues.	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  are	  associated	  with	  maladaptive	  behaviors	  and	  obesity.	  J.	  Clin.	  Invest.	  2012	  Nov	  19;122(12):4732–6.	  	  15.	   Melville	  CA,	  Hamilton	  S,	  Hankey	  CR,	  Miller	  S,	  Boyle	  S.	  The	  prevalence	  and	  determinants	  of	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Tables	  and	  Figures:	  



























screened	  DD/ID	   EU	  Consort.	   8.6	   42	   0.14;	  12;	  1e-­‐10	   20/22	   7/17	  (9:8)	   30635	  	   Literature	   27.6	   11	   NA	   4/1	   2/3	  (0:3)	   NA	  ASD	   Literature	   6	   1	   0.2;	  18;	  0.07	   1/0	   0/0	   510	  ADHD	   Literature	   8	   1	   0.2;	  15;	  0.08	   1/0	   0/0	   591	  General	  population	   Literature	  (Decode)	   50.1	   4	   0.01;	  -­‐;	  -­‐	   1/3	   0/0	   36301	  
Carriers	  TOTAL	   	   -­	   59	   -­	   27/26	   9/20	  (9:11)	   67767	  



























screened	  DD/ID	   EU	  Consort.	   7.92	   26	   0.08,	  2.6,	  5e-­‐03	   13/13	   1/13	  (9:4)	   30635	  	   Literature	   NA	   5	   NA	   NA	   1/1	  (1:0)	   NA	  ASD	   Literature	   NA	   0	   NA	   0/0	   0/0	   510	  ADHD	   Literature	   NA	   0	   NA	   0/0	   0/0	   591	  General	  population	   Literature	  (Decode)	   51.9	   12	   0.03;	  -­‐;	  -­‐	   4/8	   0/0	   36301	  
Carriers	  TOTAL	   	   -­	   43	   -­	   17/21	   2/14	  (10:4)	   67767	  *:	  cases	  where	  data	  was	  missing	  for	  inheritance	  are	  not	  included,	  %	  :	  frequency	  of	  carriers,	  OR	  :	  Odds	  Ratio,	  p	  :	  p-­‐value,	  enrichment	  of	  the	  CNV	  compared	  to	  the	  frequency	  in	  the	  general	  population	  (Fischer’s	  exact	  test),	  DD/ID	  :	  Developmental	  Delay/Intellectual	  Disability,	  ASD	  :	  Autism	  Spectrum	  Disorder,	  ADHD	  :	  Attention	  Deficit	  Hyperactivity	  Disorder,	  NA	  :	  non-­‐available	  or	  not	  applicable	  
Table	  2	   Medical	  and	  behavioral	  symptoms	  in	  deletion	  and	  duplication	  carriers	  
	  
Pathology Del Dup 
   
Neurologic : 16/55 (29.1%) 7/31 (22.6%) 
Epilepsy 4/55 (7.3%) 4/31 (12.9%) 
Hypotonia 11/55 (20%) 2/31 (6.5%) 
Ataxia 1/55 (1.8%) 1/31 (3.2%) 
   
Behavorial : 32/55 (58.2%) 17/31 (54.8%) 
ASD/PDD 10/55 (18.2%) 5/31 (16.1%) 
ADHD/ADD 11/55 (20%) 4/31 (12.9%) 
Other 11/55 (20%) 8/31 (25.8%) 
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BP1 BP2 BP3 
chr16 (p11.2) 16p13.3 16p13.2 13.13 13.12 16p12.3 16p12.1 16p11.2 16p11.1 q11.1 16q11.2 16q12.1 16q12.2 16q13 16q21 16q22.1 16q22.3 16q23.1 q23.2 q23.3 q24.1
BP4 
Figure	  1	  The	  16p11.2	  locus.	  Highly	  homologous	  blocks	  of	  low	  copy	  repeats	  (LCRs)	  may	  act	  as	  a	  substrate	  for	  	  	   non-­‐allelic	  homologous	  recombination,	  predisposing	  to	  genomic	  disorders.	  Five	  LCRs	  have	  been	  	  	   defined	  as	  mediators	  of	  recurrent	  and	  clinically	  relevant	  imbalances	  within	  the	  16p11.2	  chromosomal	  band.	  To	  	   clarify	  the	  terminology,	  we	  propose	  to	  number	  these	  “recombination	  hotspots”	  from	  telomere	  to	  centromere	  as	  	   breakpoints	  BP1	  to	  BP5.	  The	  current	  study	  describes	  only	  features	  associated	  with	  the	  distal	  220	  kb	  recurrent	  	   deletion	  or	  duplication,	  containing	  the	  SH2B1	  gene,	  delineated	  by	  BP2	  and	  BP3	  at	  genome	  sequence	  coordinates	  	   28.7-­‐28.9	  Mb,	  respectively.	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Figure	  8.	  BMI	  Z-­score	  stratified	  by	  16p11.2	  loci	  and	  copy	  number	  Figure	  8	  shows	  BMI	  Z-­‐score	  in	  function	  of	  CNV.	  Darkred	  and	  darkblue	  boxplots,	  showing	  respectively	  deletions	  and	  duplications	  carriers	  of	  the	  “classic”	  region	  (29.5-­‐30.1).	  Lightred	  and	  lightblue	  :	  deletions	  and	  duplications	  carriers	  of	  the	  SH2B1	  region.	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Cohorts	  :	  Concerning	  the	  general	  population	  cohort,	  and	  more	  specifically	  deCODE	  :	  Patients	  and	  controls	  were	  all	  Icelandic	  and	  were	  recruited	  from	  all	  over	  Iceland.	  All	  participants	  with	  ADHD	  met	  DSM-­‐IV	  criteria	  for	  ADHD	  (477	  combined	  type,	  250	  inattentive	  type,	  58	  hyperactive-­‐impulsive	  type,	  40	  unspecified).	  ADHD	  subjects	  were	  recruited	  from	  outpatient	  pediatric,	  child,	  and	  adult	  psychiatry	  clinics	  in	  Iceland,	  and	  diagnoses	  had	  been	  made	  on	  the	  basis	  of	  standardized	  diagnostic	  assessments	  and	  had	  been	  reviewed	  by	  experienced	  clinicians.	  Autistic	  individuals	  (n=351)	  met	  Autism	  Diagnostic	  Interview	  Revised	  (ADI-­‐R)	  criteria	  and	  were	  ascertained	  through	  the	  State	  Diagnostic	  Counselling	  Center	  and	  the	  Department	  of	  Child	  and	  Adolescent	  Psychiatry	  in	  Iceland.	  schizophrenia	  diagnoses	  were	  assigned	  according	  to	  Research	  Diagnostic	  Criteria	  (RDC)	  	  through	  the	  use	  of	  the	  Schedule	  for	  Affective	  Disorders	  and	  Schizophrenia	  Lifetime	  Version	  (SADS-­‐L).	  Schizophrenia	  patients	  (n=657)	  were	  recruited	  from	  outpatient	  pediatric,	  child,	  and	  adult	  psychiatry	  clinics,	  and	  diagnoses	  had	  been	  made	  on	  the	  basis	  of	  standardized	  diagnostic	  assessments	  and	  had	  been	  reviewed	  by	  experienced	  clinicians.	  Recruitment	  of	  the	  psychiatric	  patients	  at	  deCODE	  has	  been	  described	  in	  more	  details	  elsewhere,	  ADHD,	  ASD	  schizophrenia	  and	  the	  control	  population.	  All	  participants,	  cases	  and	  controls,	  returned	  signed	  informed	  consents	  prior	  to	  participation	  in	  the	  study.	  All	  personal	  identifiers	  associated	  with	  medical	  information,	  questionnaire	  results,	  and	  blood	  samples	  were	  encrypted	  according	  to	  the	  standards	  set	  by	  the	  Data	  Protection	  Committee	  of	  Iceland.	  All	  procedures	  related	  to	  this	  study	  have	  been	  approved	  by	  the	  Data	  Protection	  Authority	  and	  National	  Bioethics	  Committee	  of	  Iceland.	  
	  
Figures	  :	  
Supplemental	  Figure	  1	  
	  Coverage	  of	  the	  16:	  28.3-­‐29.5	  region	  by	  several	  array	  CGH	  and	  SNP	  array	  platforms	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Supplemental	  Figure	  2	  
	  Supplemental	  Figure	  2	  shows	  HC	  in	  function	  of	  age.	  	  
Supplemental	  Figure	  3	  
	  Supplemental	  Figure	  3	  shows	  HC	  Z-­‐score	  in	  function	  of	  age.	  	  	  	   	  
